radiolabeling

bring ideas to life – for a better health worldwide Radiopharmaceuticals CDMO / CMOProducts See what makes the Difference Radelumin® is indicated for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings: • Primary staging of patients with high-risk PCa prior to primary curative therapy• Suspected PCa recurrence in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy.More Radiopharmaceutical Partner from Development to Global Supply ABX is a trusted partner in radiopharmaceutical innovation, combining 30 years of experience with expertise across development, manufacturing, regulatory support and global supply. Our integrated portfolio of radiopharmaceuticals, CDMO / CMO services and products helps bring.

analytical procedure developmentglobal distributionGMP manufacturingproject managementQC method developmentradiopharmaceutical developmentregulatory supportTech transfer

Archeus Technologies is a radiopharmaceutical company developing differentiated radiopharmaceutical therapies (RPT) for some of the most difficult-to-treat cancers. Its growing pipeline includes novel RPT agents and companion diagnostic assets with the potential to provide curative responses for patients with advanced disease.

clinical trial designpreclinical researchradioanalytical methodsradiopharmaceutical developmenttargeted radionuclide therapy

Darya Pharmaceuticals is a client-focused, U.S.-based company providing comprehensive, end-to-end preclinical radiopharmaceutical research and development services, from small molecule and peptide preparation through in vivo assays and regulatory consultation.

biodistribution and dosimetrychemistry synthesisin vitro assaysin vivo assaysnon-GLP pharm/tox studiesphage displayprotein expressionregulatory consultation